Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Min Ding
Min Ding, Shanghai CN
| Patent application number | Description | Published |
|---|---|---|
| 20110102293 | Antenna Assembly - An antenna module that includes two directional antennae arranged in a back-to-back manner, and a converter. The converter realizes conversion between an omnidirectional antenna mode and a directional antenna mode by switching on two directional antennae simultaneously or by switching on one of the directional antennas. Alternatively, the antenna module includes a horizontal polarization antenna, a vertical polarization antenna and a converter, where the converter provides the conversion between the horizontal polarization antenna mode and the vertical polarization antenna mode by switching on the horizontal polarization antenna or the vertical polarization antenna. | 05-05-2011 |
Min Ding, Tarrytown, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20100105743 | Pharmaceutical compositions and methods for stabilizing the same - Pharmaceutical compositions, and a method of stabilizing pharmaceutical compositions having clevidipine, or any pharmaceutically acceptable salt thereof, as the active ingredient is described. The method includes the slowing down or inhibiting of the oxidation pathway of clevidipine. This can be accomplished by reducing the amount the pharmaceutical composition is exposed to oxygen and/or light during the manufacturing and storing processes. According to this method, oxygen must be removed or replaced, or light must be sufficiently blocked such that light energy cannot reach the active ingredient of the composition, or is reduced to a level that the light-induced oxidation reaction converting clevidipine to H324/78 is minimized, such that the total detectable level of H324/78 in a given composition sample does not exceed about 0.2% on a weight-by-weight basis, or the ratio of clevidipine to H324/78 is equal to or greater than about 450 to 1 on a weight-to-weight basis. | 04-29-2010 |
| 20100113534 | Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same - A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1. | 05-06-2010 |
Min Ding, Glastonbury, CT US
| Patent application number | Description | Published |
|---|---|---|
| 20080226591 | Compounds for the Treatment of Hepatitis C - The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. | 09-18-2008 |
| 20080226592 | Compounds for the Treatment of Hepatitis C - The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. | 09-18-2008 |
| 20080227769 | Compounds for the Treatment of Hepatitis C - The invention encompasses compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. | 09-18-2008 |
| 20090162318 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors - The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. | 06-25-2009 |
| 20090280083 | Compounds for the Treatment of Hepatitis C - The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. | 11-12-2009 |
| 20100080772 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 04-01-2010 |
| 20110207749 | Glycine Chroman-6-Sulfonamides for Use as Inhibitors of Diacylglycerol Lipase - The present disclosure is generally directed to compounds that can inhibit DAGLα and/or β activity, compositions comprising such compounds, and methods for inhibiting DAGLα and/or β activity. | 08-25-2011 |
| 20110207772 | Glycine Chroman-6-Sulfonamides for Use as Inhibitors of Diacylglycerol Lipase - The present disclosure is generally directed to compounds that can inhibit DAGLα and/or β activity, compositions comprising such compounds, and methods for inhibiting DAGLα and/or β activity. | 08-25-2011 |
Min Ding, Austin, TX US
| Patent application number | Description | Published |
|---|---|---|
| 20100052106 | PACKAGE DEVICE HAVING CRACK ARREST FEATURE AND METHOD OF FORMING - A package device has a package substrate, a semiconductor die on the package substrate, and a molding compound on the package substrate and over the semiconductor die. The semiconductor die has a last passivation layer, an active circuit region in an internal portion of the die, an edge seal region along a periphery of the die, and a structure over the edge seal region extending above the last passivation layer, covered by the molding compound, and comprising a polymer material. The structure may extend at least five microns above the last passivation layer. The structure stops cracks in the molding compound from reaching the active circuit region. The cracks, if not stopped, can reach wire bonds in the active region and cause them to fail. | 03-04-2010 |
Min Ding, Vancouver CA
| Patent application number | Description | Published |
|---|---|---|
| 20090110267 | Automated texture mapping system for 3D models - A camera pose may be determined automatically and is used to map texture onto a 3D model based on an aerial image. In one embodiment, an aerial image of an area is first determined. A 3D model of the area is also determined, but does not have texture mapped on it. To map texture from the aerial image onto the 3D model, a camera pose is determined automatically. Features of the aerial image and 3D model may be analyzed to find corresponding features in the aerial image and the 3D model. In one example, a coarse camera pose estimation is determined that is then refined into a fine camera pose estimation. The fine camera pose estimation may be determined based on the analysis of the features. When the fine camera pose is determined, it is used to map texture onto the 3D model based on the aerial image. | 04-30-2009 |
Min Ding, Chalfont, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20110276682 | System and Method for Determining Application Dependency Paths in a Data Center - A method and a system are disclosed for determining application dependency paths in a data center. The method and the system captures application traffic volume data on the servers with switches and monitoring agents; generates an application traffic matrix of all the components of the applications based on the application traffic volume data; estimates the number of the applications in the data center from the traffic matrix with a Rank Estimation via Singular Value Decomposition or Power Factorization Residue Errors process; and decomposes the traffic matrix into a first matrix and a second matrix with a non-negative matrix factorization process using the estimated number of applications. The first matrix represents a set of the components belonging to each of the applications and the second matrix represents the amount of traffic generated by each application over time. Any noise in the first and second matrices is removed with a concurrent volumes ratios based correlation process. | 11-10-2011 |